LITS

#4418
Lite Strategy, Inc. - Common Stock
0.9 8 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.98
0.98
Jahresspanne
0.69
3.23
Tagesänderung
-2.00%
Monatliche Änderung
-1.01%
6 month change
-9.26%
Jahresänderung
-67.11%
Vorheriger Schlusskurs
1.0 0
Open
0.9 8
Tief
0.9 8
Hoch
0.9 8
Volumen
2
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 16 December 2021

Full document

SEC Filing Summary: MEI Pharma, Inc. (Form 8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by MEI Pharma, Inc. on December 16, 2021. The filing documents corporate governance actions taken on the same date, specifically the approval of Bylaw amendments and the results of the Company's Annual Meeting of Stockholders.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Corporate Actions

  • Bylaw Amendment: The Board of Directors approved an amendment to the Bylaws to change the title from "chairman" to "chair."
  • Annual Meeting Attendance: 93,303,972 shares were represented at the meeting out of 112,705,170 shares outstanding and entitled to vote.
  • Director Elections: Three directors were elected to three-year terms expiring in 2025:
    • Charles V. Baltic III (69,627,455 For)
    • Nicholas R. Glover (68,905,944 For)
    • Frederick W. Driscoll (69,788,794 For)
  • Executive Compensation: The advisory vote on executive compensation was approved with 67,699,171 votes For.
  • Auditor Ratification: The appointment of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2022, was ratified with 92,510,833 votes For.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the Annual Meeting and the Bylaw amendment.

Key Facts for Investor Verification

  • Verify the effective date of the Bylaw amendment regarding the "chair" title.
  • Confirm the tenure of the newly elected directors (expiring at the 2025 annual meeting).
  • Note the significant number of Broker Non-Votes (23,290,193) recorded for all proposals, indicating shares held by brokers that did not receive voting instructions.
  • Confirm BDO USA, LLP's role as the auditor for the fiscal year ending June 30, 2022.